701 results on '"Nordenskjöld, Bo"'
Search Results
2. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
3. Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature
4. Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
5. MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
6. Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
7. PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients
8. Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
9. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk
10. Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit
11. Prediction of Tamoxifen Benefit in Premenopausal Breast Cancer Patients Evaluated by Three Methods for Determination of Hormone Receptor Status
12. Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial
13. The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype
14. PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer
15. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up
16. Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer - data from the randomized SBII:2 trial
17. Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
18. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
19. Supplementary Figures 1-3 from ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer
20. Data from Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
21. Supplementary Data from Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
22. Abstract P2-03-04: Long-Term Benefit from Adjuvant Tamoxifen in Luminal A and Luminal B Breast Cancer Patients
23. Abstract P3-05-03: Long-term survival and intra-tumor heterogeneity of progesterone receptor expression in estrogen receptor-positive/progesterone receptor-positive premenopausal women with breast cancer
24. Abstract P2-03-11: Differential Long-Term Benefit from Adjuvant Tamoxifen Therapy in Estrogen Receptor (ER)-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Premenopausal and Postmenopausal Breast Cancer Patients
25. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial
26. Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades
27. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial
28. Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer
29. Abstract PD9-05: Prognostic and tamoxifen-predictive effect of PAM50 and ROR score in premenopausal women included in the randomised SBII:2 trial
30. Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
31. C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
32. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer
33. Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
34. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
35. Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy
36. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial
37. IP6K2 predicts favorable clinical outcome of primary breast cancer
38. Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up
39. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer
40. Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen
41. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial
42. In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients
43. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information
44. Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer
45. IP6K2 predicts favorable clinical outcome of primary breast cancer
46. Abstract PS5-09: Tumour infiltrating lymphocytes of prognostic value in different molecular breast cancer subgroups and as a suggestive predictive factor for adjuvant tamoxifen benefit in premenopausal patients after 30 years follow-up
47. Exploring the two-gene ratio in breast cancer—independent roles for HOXB13 and IL17BR in prediction of clinical outcome
48. RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer
49. Additional file 1 of Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up
50. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.